P/B
6,8
REGENXBIO
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
$488.5M
Market Cap • 9/25/2026
2008
(18 years)
Founded
2015
(11 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
2,8
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,4
EPS
—
Market Cap
Market Cap
488,5M
EV
633,4M
EV/Revenue
3,6
EV/EBITDA
-4,3
EV/EBIT
-3,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-4%
Total Yield
-4%
Payout
0%
Retained Earnings
-1,2B
Profitability
Gross Margin
86,4%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
131,3%
Capex/Revenue
1,7%
Capex/D&A
19,5%
Capex/OCF
-1,2%
SBC/OCF
—
% PPE
36,8%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
1,6%
CAGR Op. Income 5Y
3,8%
CAGR Net Income 5Y
6,2%
CAGR EPS 5Y
1,2%
CAGR OCF 5Y
24,7%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
2,9
Quick Ratio
2,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!